News Apnimed IPO raises $192m, as three other biotechs set terms Sleep apnoea drug developer Apnimed has completed its IPO, raising $192m, while Braveheart, Attovia, and Vogenx reveal their terms.
News Scribe raises $155m in IPO, as Apnimed pitches for $150m Gene-editing specialist Scribe becomes the 14th biotech to list on the Nasdaq this year, as sleep apnoea drug developer Apnimed prices its listing.
News Sleep apnoea drug firm Apnimed files for IPO Apnimed has joined the IPO queue on the Nasdaq, hoping to raise additional funding for its late-stage oral therapy for obstructive sleep apnoea.
News CNS-focused Supernus and Indivior agree merger terms Supernus Pharma and Indivior have signed an all-stock merger agreement that would establish a new CNS-focused company with annual sales of $2.2bn.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.